Evidence map›Paper›PMID 31534203›Full record

ArticleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2020

Interobserver variability in upfront dichotomous histopathological assessment of ductal carcinoma in situ of the breast: the DCISion study.

Hélène Dano, Serdar Altinay, Laurent Arnould, Noella Bletard, Cecile Colpaert, Franceska Dedeurwaerdere, Benjamin Dessauvagie, Valérie Duwel, Giuseppe Floris, Stephen Fox and 30 more

Open access · bronzeAbstract readMulticenter Study
In one paragraph

Article in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 39 citations in OpenAlex.

  1. Effects of Prior Diagnosis on Second Opinions and Pathologist Viewing Behaviors: Results from a Randomized Trial in Breast Pathology.Medical decision making : an international journal of the Society for Medical Decision Making · 2026
    Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Risk perception of patients with ductal carcinomaHistology and histopathology · 2025
    Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Morphological intratumor heterogeneity in ductal carcinoma in situ of the breast.Virchows Archiv : an international journal of pathology · 2021
    Article
  16. Article
  17. Article
  18. Immune response and stromal changes in ductal carcinoma in situ of the breast are subtype dependent.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2020
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

40 authors at 20 institutions in 9 countries.

Hélène DanoDepartment of pathology, Cliniques universitaires Saint-Luc Bruxelles, Avenue Hippocrate 10, 1200, Woluwé-Saint-Lambert, Belgium.
Serdar Altinay *Department of Pathology, Bakirköy Dr. Sadi Konuk Health Application and Research Center, University of Health Sciences, 34147, Istanbul, Turkey.
Laurent Arnould *Département de Biologie et de Pathologie des Tumeurs, Centre George-François Leclerc, 1 Rue Pr. Marion, 21000, Dijon, France.
Noella Bletard *Department of Pathology, CHU de Liège-site Sart Tilman, Avenue de l'Hòpital 1, 4000, Liège, Belgium.
Cecile Colpaert *Department of Pathology, GZA/ZNA Hospitals, 2610, Wilrijk, Belgium.
Franceska Dedeurwaerdere *Department of Pathology, AZ Delta, Westlaan 123, 8800, Roeselare, Belgium.
Benjamin Dessauvagie *Division of Pathology and Laboratory Medicine, Medical School, The University of Western Australia, Crawley, WA, 6009, Australia.
Valérie Duwel *Department of pathology, AZ Klina Brasschaat, Augustijnslei 100, 2930, Brasschaat, Belgium.
Giuseppe Floris *Department of pathology, University Hospitals Leuven, KU Leuven-University of Leuven, Herestraat 49, 3000, Leuven, Belgium.ORCID http://orcid.org/0000-0003-2391-5425
Stephen Fox *Department of Pathology, Peter MacCallum Cancer Center and the University of Melbourne, Melbourne, VIC, 3000, Australia.ORCID http://orcid.org/0000-0002-7648-8896
Clara Gerosa *Department of Pathology, University of Cagliari, AOU San Giovanni di Dio, Via Ospedale 54, 09124, Cagliari, Italy.
Shabnam Jaffer *Department of Pathology, Mount Sinai Hospital and Icahn School of Medicine, New York, NY, 10029, USA.
Eline Kurpershoek *Pathan BV, Kleiweg 500, 3045 PM, Rotterdam, The Netherlands.
Magali Lacroix-Triki *Department of Pathology, Gustave-Roussy Cancer Campus, 114 Rue Edouard-Vaillant, 94805, Villejuif, France.
Andoni Laka *Department of Pathology, Clinique Notre-Dame de Grâce (CNDG), Chaussée de Nivelles 212, 6041, Gosselies, Belgium.
Kathleen Lambein *Department of pathology, St. Lucas Hospital, Groenebriel 1, 9000, Ghent, Belgium.
Gaëtan Marie MacGrogan *Surgical Pathology Unit, Department of Pathobiology, Institut Bergonié, F-33076, Bordeaux, France.
Caterina Marchió *Department of Medical Sciences, University of Turin, 10126, Torino, Italy.
Dolores Martin Martinez *Curepath, Rue de Borfilet 12A, 6040, Jumet, Belgium.
Sharon Nofech-Mozes *Department of Laboratory Medicine and Molecular Diagnostics, Sunnybrook Health Sciences Center, University of Toronto, Toronto, Ontario, ON, M4N 3M5, Canada.
Dieter Peeters *Department of Pathology, AZ St. Maarten, Liersesteenweg 435, 2800, Mechelen, Belgium.
Alberto Ravarino *Department of Pathology, University of Cagliari, AOU San Giovanni di Dio, Via Ospedale 54, 09124, Cagliari, Italy.
Emily Reisenbichler *Department of Pathology, Yale School of Medicine, Yale New Haven Hospital, 310 Cedar Street, New Haven, CT, 06510, USA.ORCID http://orcid.org/0000-0002-1570-6538
Erika Resetkova *The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Souzan Sanati *Department of Pathology and Immunology, Washington University School of Medicine, 660S Euclid Boulevard, St. Louis, MO, 63110, USA.
Anne-Marie Schelfhout *Department of Pathology, Onze-Lieve-Vrouwziekenhuis Aalst, Moorselbaan 164, 9300, Aalst, Belgium.
Vera Schelfhout *Department of Pathology, AZ St. Maarten, Liersesteenweg 435, 2800, Mechelen, Belgium.
Abeer M Shaaban *Department of Cellular Pathology, Queen Elizabeth Hospital Birmingham, University of Birmingham, Birmingham, B15 2GW, UK.
Renata Sinke *Pathan BV, Kleiweg 500, 3045 PM, Rotterdam, The Netherlands.
Claudia Maria Stanciu-Pop *Department of Pathology, CHU UCL Namur, Site Godinne, Avenue Docteur G. Thérasse 1, 5530, Yvoir, Belgium.
Claudia Stobbe *Pathan BV, Kleiweg 500, 3045 PM, Rotterdam, The Netherlands.
Carolien H M van Deurzen *Department of Pathology, Erasmus Medical Center Rotterdam, Doctor Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands.
Koen Van de Vijver *Department of Pathology, Ghent University Hospital, C. Heymanslaan 10, 9000, Ghent, Belgium.ORCID http://orcid.org/0000-0002-2026-9790
Anne-Sophie Van Rompuy *Department of pathology, University Hospitals Leuven, KU Leuven-University of Leuven, Herestraat 49, 3000, Leuven, Belgium.
Stephanie Verschuere *Department of Pathology, AZ Delta, Westlaan 123, 8800, Roeselare, Belgium.
Anne Vincent-Salomon *Pôle de Médicine Diagnostique & Théranostique, INSERM U934, Institut Curie, 26 Rue d'Ulm, 75248, Paris, Cedex 05, France.
Hannah Wen *Department of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA.
Caroline Bouzin2IP IREC Imaging Platform, Institute of Clinical and Experimental Research (IREC), Université catholique de Louvain, Avenue Hippocrate 55, 1200, Brussels, Belgium.ORCID http://orcid.org/0000-0003-0694-1947
Christine GalantDepartment of pathology, Cliniques universitaires Saint-Luc Bruxelles, Avenue Hippocrate 10, 1200, Woluwé-Saint-Lambert, Belgium.
Mieke R Van BockstalDepartment of pathology, Cliniques universitaires Saint-Luc Bruxelles, Avenue Hippocrate 10, 1200, Woluwé-Saint-Lambert, Belgium. mieke.vanbockstal@uclouvain.be.ORCID http://orcid.org/0000-0003-4498-928X
Cliniques Universitaires Saint-Luc · BEPathoFinder (Netherlands) · NLAZ Delta · BEAZ Sint-Lucas · BEKU Leuven · BEUniversity of Cagliari · ITAZ Klina · BEBakırköy Dr.Sadi Konuk Eğitim ve Araştırma Hastanesi · TRCandiolo Cancer Institute · ITCentre Georges François Leclerc · FRCHU Dinant Godinne UCL Namur · BEErasmus University Rotterdam · NLGhent University Hospital · BEGZA Ziekenhuizen Campus Sint-Augustinus · BEHistoGeneX (Belgium) · BEInserm · FRInstitut Bergonié · FRInstitut Gustave Roussy · FRMemorial Sloan Kettering Cancer Center · USMount Sinai Hospital · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
NCATS NIH HHS UL1 TR001863NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Histopathological assessment of ductal carcinoma in situ, a nonobligate precursor of invasive breast cancer, is characterized by considerable interobserver variability. Previously, post hoc dichotomization of multicategorical variables was used to determine the "ideal" cutoffs for dichotomous assessment. The present international multicenter study evaluated interobserver variability among 39 pathologists who performed upfront dichotomous evaluation of 149 consecutive ductal carcinomas in situ. All pathologists independently assessed nuclear atypia, necrosis, solid ductal carcinoma in situ architecture, calcifications, stromal architecture, and lobular cancerization in one digital slide per lesion. Stromal inflammation was assessed semiquantitatively. Tumor-infiltrating lymphocytes were quantified as percentages and dichotomously assessed with a cutoff at 50%. Krippendorff's alpha (KA), Cohen's kappa and intraclass correlation coefficient were calculated for the appropriate variables. Lobular cancerization (KA = 0.396), nuclear atypia (KA = 0.422), and stromal architecture (KA = 0.450) showed the highest interobserver variability. Stromal inflammation (KA = 0.564), dichotomously assessed tumor-infiltrating lymphocytes (KA = 0.520), and comedonecrosis (KA = 0.539) showed slightly lower interobserver disagreement. Solid ductal carcinoma in situ architecture (KA = 0.602) and calcifications (KA = 0.676) presented with the lowest interobserver variability. Semiquantitative assessment of stromal inflammation resulted in a slightly higher interobserver concordance than upfront dichotomous tumor-infiltrating lymphocytes assessment (KA = 0.564 versus KA = 0.520). High stromal inflammation corresponded best with dichotomously assessed tumor-infiltrating lymphocytes when the cutoff was set at 10% (kappa = 0.881). Nevertheless, a post hoc tumor-infiltrating lymphocytes cutoff set at 20% resulted in the highest interobserver agreement (KA = 0.669). Despite upfront dichotomous evaluation, the interobserver variability remains considerable and is at most acceptable, although it varies among the different histopathological features. Future studies should investigate its impact on ductal carcinoma in situ prognostication. Forthcoming machine learning algorithms may be useful to tackle this substantial diagnostic challenge.

Indexed as

PathologistsBiopsyBreast NeoplasmsCalcinosisCarcinoma, Intraductal, NoninfiltratingCell NucleusFemaleHumansLymphocytes, Tumor-InfiltratingNecrosisObserver VariationPredictive Value of TestsPrognosisReproducibility of ResultsRisk AssessmentRisk Factors

Identifiers

PMID31534203
PMCPMC7983551
OpenAlexW2973452191

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.